These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35548241)

  • 21. Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.
    Liu B; Gai K; Qin H; Liu X; Cao Y; Lu Q; Lu D; Chen D; Shen H; Song W; Zhang Y; Wang X; Xu H; Zhang Y
    Eur J Med Chem; 2018 Mar; 148():95-105. PubMed ID: 29454920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
    Chahine EB; Kelley D; Childs-Kean LM
    Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bifluoride-catalysed sulfur(VI) fluoride exchange reaction for the synthesis of polysulfates and polysulfonates.
    Gao B; Zhang L; Zheng Q; Zhou F; Klivansky LM; Lu J; Liu Y; Dong J; Wu P; Sharpless KB
    Nat Chem; 2017 Nov; 9(11):1083-1088. PubMed ID: 29064495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulfonyl fluorides as privileged warheads in chemical biology.
    Narayanan A; Jones LH
    Chem Sci; 2015 May; 6(5):2650-2659. PubMed ID: 28706662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.
    Geddawy A; Ibrahim YF; Elbahie NM; Ibrahim MA
    J Transl Int Med; 2017 Mar; 5(1):8-17. PubMed ID: 28680834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
    King JR; Menon RM
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):201-205. PubMed ID: 28263457
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.
    Mogalian E; German P; Kearney BP; Yang CY; Brainard D; Link J; McNally J; Han L; Ling J; Mathias A
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SuFEx: a metal-free click ligation for multivalent biomolecules.
    Dondoni A; Marra A
    Org Biomol Chem; 2017 Feb; 15(7):1549-1553. PubMed ID: 28116403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleophilic Deoxyfluorination of Phenols via Aryl Fluorosulfonate Intermediates.
    Schimler SD; Cismesia MA; Hanley PS; Froese RD; Jansma MJ; Bland DC; Sanford MS
    J Am Chem Soc; 2017 Feb; 139(4):1452-1455. PubMed ID: 28111944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide.
    Kang IJ; Hsu SJ; Yang HY; Yeh TK; Lee CC; Lee YC; Tian YW; Song JS; Hsu TA; Chao YS; Yueh A; Chern JH
    J Med Chem; 2017 Jan; 60(1):228-247. PubMed ID: 27966956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
    Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
    Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
    Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
    J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New potent biaryl sulfate-based hepatitis C virus inhibitors.
    You Y; Kim HS; Bae IH; Lee SG; Jee MH; Keum G; Jang SK; Kim BM
    Eur J Med Chem; 2017 Jan; 125():87-100. PubMed ID: 27657807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SuFEx Click: New Materials from SO
    Yatvin J; Brooks K; Locklin J
    Chemistry; 2016 Nov; 22(46):16348-16354. PubMed ID: 27557871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph.
    Meanwell NA
    J Med Chem; 2016 Aug; 59(16):7311-51. PubMed ID: 27501244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C.
    Hill A; Simmons B; Gotham D; Fortunak J
    J Virus Erad; 2016 Jan; 2(1):28-31. PubMed ID: 27482432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.
    Bell AM; Wagner JL; Barber KE; Stover KR
    Int J Hepatol; 2016; 2016():3852126. PubMed ID: 27403342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in Antiviral Therapy for Chronic Hepatitis C.
    Tamori A; Enomoto M; Kawada N
    Mediators Inflamm; 2016; 2016():6841628. PubMed ID: 27022210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.